Definitive Healthcare Corp. reports developments in healthcare market data, analytics, and commercial intelligence for organizations operating on the business side of healthcare. Its SaaS-based platform and related solutions support use cases such as market selection, go-to-market planning, provider targeting, affiliation analysis, prescription-pattern visibility, Key Opinion Leader identification, and workflow data enrichment.
Recurring news for DH includes quarterly and annual financial results, guidance commentary, customer wins and renewals across life sciences and health-system markets, expansions involving products such as Monocl and Population Intelligence, data-integration use cases, and investor conference presentations. Company updates also describe subscription revenue trends, adjusted profitability measures, cash flow, and commercial execution across new logos and existing customers.
Definitive Healthcare (DH) has joined the Network Advertising Initiative, an industry organization focused on data privacy in digital advertising. The company said membership reinforces its commitment to responsible handling of sensitive healthcare data and compliance with federal and state data protection requirements.
The NAI plans to collaborate with Definitive Healthcare on policies and data governance for consumer data used in health-related advertising. Earlier this year, the NAI introduced a framework to help businesses identify sensitive healthcare data.
Definitive Healthcare (DH) received a non-binding going‑private proposal from Advent International, dated September 1, 2026, to acquire all outstanding Class A common shares and AIDH TopCo Definitive OpCo units not already owned by Advent or founder Jason Krantz for $1.02 per share in cash, or an equivalent amount per unit.
A special committee of independent, disinterested directors is reviewing the proposal with independent legal and financial advisors and will evaluate strategic alternatives. The committee stresses that no decision has been made, there is no assurance any transaction will occur, and shareholders are not required to take any action at this time.
Definitive Healthcare (DH) appointed Clay Ritchey as Chief Executive Officer and Board member, effective September 8, 2026, succeeding Kevin Coop, who departed on August 31, 2026 after serving as CEO since June 2024.
Ritchey brings over 25 years of experience in healthcare master data and technology. He most recently served as CEO of Verato and previously held senior roles at Evariant, Imprivata, Equinox Healthcare, Hill-Rom and Kronos. The company highlights his track record in driving profitable growth and his belief that AI will reshape healthcare, aligning with Definitive Healthcare’s upcoming AI-powered platform that combines proprietary healthcare data with conversational AI and workflows.
Definitive Healthcare (Nasdaq: DH) reported second quarter 2026 revenue of $55.2 million, down 9% from $60.8 million a year earlier but within its guidance range. Net loss improved to $(7.5) million (14% margin) versus $(9.3) million (15% margin) in Q2 2025.
Adjusted EBITDA was $14.6 million, or 26% of revenue, compared with $18.7 million and a 31% margin a year ago. Cash flow from operations reached $11.5 million, and unlevered free cash flow was $11.6 million. The company highlighted win-back and expansion deals and launched Turbo, an AI-powered healthcare intelligence platform.
For full-year 2026, Definitive Healthcare expects revenue of $220–$222 million, adjusted EBITDA of $57–$59 million (26–27% margin), and adjusted net income of $27–$29 million.
Definitive Healthcare (Nasdaq: DH) has launched an early adopter program for a new AI-powered healthcare intelligence platform, offering select organizations early access ahead of planned general availability in late 2026.
The platform combines Definitive Healthcare’s data assets with conversational AI to unify claims, provider, consumer, affiliation, and KOL datasets. It is designed to help users size market opportunities, optimize sales territories, prioritize high-value prospects, find decision makers, and reduce patient leakage. Early adopter customers across health systems, life sciences, and other healthcare-focused industries will begin participating in August 2026, providing feedback to refine the final product.
Definitive Healthcare (Nasdaq: DH) will report financial results for its second quarter ended June 30, 2026 on Monday, August 10, 2026, after market close. The company will host a conference call and webcast at 5:00 PM ET / 2:00 PM PT, with live access via its Investor Relations website, domestic and international dial-ins, and a replay available through September 9, 2026 using passcode 1765#.
Definitive Healthcare (Nasdaq: DH) disclosed that its Human Capital Management and Compensation Committee granted inducement equity awards in connection with hiring a new senior leader, in line with Nasdaq Listing Rule 5635(c)(4). The company granted 1,063,830 time-based RSUs to Srinivas Attipalli, its new SVP and Head of AI & Data - Product, effective July 24, 2026.
According to Definitive Healthcare, the award was individually negotiated, made under the company’s 2023 Inducement Plan, and is subject to an applicable award agreement. The RSUs vest 25% on June 1, 2027, with the remaining 75% vesting in equal quarterly installments of 6.25% until fully vested, contingent on continued employment.
Restaurant365 appointed Kate Hastings as Chief Customer Officer to lead all post-sale customer functions, including success, support, onboarding, implementation, and professional services. With 15+ years of experience and prior CCO role at Definitive Healthcare (Nasdaq: DH), she will focus on driving measurable outcomes for restaurant operators amid rising costs and complexity.
Hastings will also appear at Transform 2026, Restaurant365's customer conference, November 1–3 in Scottsdale, Arizona.
Definitive Healthcare (Nasdaq: DH) announced product enhancements to strengthen its healthcare data platform and integrations. Updates include expanded Atlas All-Payor Claims coverage, a new HubSpot CRM integration, direct access to affiliated HCP data in Salesforce via DefinitiveConnect, and new AI search in Monocl ExpertInsight and the View Suite.
These enhancements aim to give organizations a more complete, connected view of the healthcare ecosystem and make insights easier to use across sales, marketing, strategy, medical affairs, and product development.
Definitive Healthcare (Nasdaq: DH) reported Q1 2026 results for the quarter ended March 31, 2026. Revenue was $55.9 million (down 6% YoY). Net loss was $(192.4) million, inclusive of $197.2 million goodwill impairment. Adjusted net income was $8.5 million; Adjusted EBITDA was $15.3 million (27% of revenue). Cash flow from operations was $11.6 million and unlevered free cash flow was $18.0 million. Q2 2026 and full‑year 2026 guidance ranges were provided, including full‑year revenue $220.0–$226.0 million.